virax/hopper drug deal poses funding issues, page-4

…I'm changing my sentiment on VHL after further DD - and pending more - Strauss.

I'm not at all comfortable with aspects of the Pathway deal and the way they were presented - or not presented - on Monday.

I need to be convinced about the robustness of the GGTI-2418 platform,

I need to know why a past license holder quit trialling.

If you and I were presiding over a potential blockbuster platform would we quit?

Of course, it's possible that the termination initiative was taken by Yale.

If so, why so?

Then there are funding/dilution issues.

Plenty for me/us to ponder.

I've yet to sell out.

Still awaiting outcome of IP review and Transgene/Novartis option deal.